Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status — Results From the EMPEROR-Reduced TrialCirculation 2020 Nov 11;[EPub Ahead of Print], SD Anker, J Butler, G Filippatos, MS Khan, N Marx, CSP Lam, S Schnaidt, AP Ofstad, M Brueckmann, W Jamal, E Bocchi, P Ponikowski, SV Perrone, JL Januzzi, S Verma, M Böhm, JP Ferreira, SJ Pocock, F Zannad, M Packer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.